558 related articles for article (PubMed ID: 30598172)
21. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?
van der Schaft J; Thijs JL; de Bruin-Weller MS; Balak DMW
Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):341-349. PubMed ID: 31145194
[TBL] [Abstract][Full Text] [Related]
22. Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches.
Moyle M; Cevikbas F; Harden JL; Guttman-Yassky E
Exp Dermatol; 2019 Jul; 28(7):756-768. PubMed ID: 30825336
[TBL] [Abstract][Full Text] [Related]
23. [Principles of modern diagnosis and treatment of atopic dermatitis and bronchial asthma: Clinical case].
Shogenova MS; Hutueva SH; Shogenova LS
Ter Arkh; 2022 Mar; 94(3):427-433. PubMed ID: 36286909
[TBL] [Abstract][Full Text] [Related]
24. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis and management of moderate to severe adult atopic dermatitis: a Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), and the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA).
Calzavara Pinton P; Cristaudo A; Foti C; Canonica GW; Balato N; Costanzo A; DE Pità O; DE Simone C; Patruno C; Pellacani G; Peris K; Girolomoni G
G Ital Dermatol Venereol; 2018 Apr; 153(2):133-145. PubMed ID: 29237258
[TBL] [Abstract][Full Text] [Related]
26. Rapid response to dupilumab treatment in children with moderate-to-severe atopic dermatitis: A case series.
Votto M; Delle Cave F; De Filippo M; Marseglia A; Marseglia GL; Brazzelli V; Licari A
Pediatr Allergy Immunol; 2022 Jan; 33 Suppl 27(Suppl 27):31-33. PubMed ID: 35080304
[TBL] [Abstract][Full Text] [Related]
27. Biologics in atopic dermatitis.
Chan S
Curr Opin Allergy Clin Immunol; 2021 Jun; 21(3):297-302. PubMed ID: 33871424
[TBL] [Abstract][Full Text] [Related]
28. Expert opinion on management of moderate-to-severe atopic dermatitis in Qatar.
Steinhoff M; Adeli M; Riad H; Allam M; Hazem A; Alsmadi R; Kamal AM; Ibrahim W; Al-Nesf MA
J Dermatolog Treat; 2023 Dec; 34(1):2251622. PubMed ID: 37700510
[TBL] [Abstract][Full Text] [Related]
29. A review of dupilumab in the treatment of atopic diseases.
Thibodeaux Q; Smith MP; Ly K; Beck K; Liao W; Bhutani T
Hum Vaccin Immunother; 2019; 15(9):2129-2139. PubMed ID: 30785362
[TBL] [Abstract][Full Text] [Related]
30. Biological Therapies for Atopic Dermatitis: A Systematic Review.
Zhou S; Qi F; Gong Y; Zhang J; Zhu B
Dermatology; 2021; 237(4):542-552. PubMed ID: 33735876
[TBL] [Abstract][Full Text] [Related]
31. Current and emerging biologics for the treatment of pediatric atopic dermatitis.
Ghamrawi R; Bell KA; Balogh EA; Strowd LC; Feldman SR
Expert Opin Biol Ther; 2020 Dec; 20(12):1435-1445. PubMed ID: 33078990
[TBL] [Abstract][Full Text] [Related]
32. Safe and effective treatment of atopic dermatitis using dupilumab over 23 months in a patient with HIV.
Lor M; Villa N; Holland V
Dermatol Ther; 2020 Nov; 33(6):e14271. PubMed ID: 32882092
[TBL] [Abstract][Full Text] [Related]
33. Burden, Control, and Treatment of Moderate to Severe Atopic Dermatitis in 2021: A United States Patient Survey Study.
Lio P; Mackie D; Bates D; Mulvihill E; Patel M; Kim Y; Shi V
J Drugs Dermatol; 2023 Feb; 22(2):119-131. PubMed ID: 36745377
[TBL] [Abstract][Full Text] [Related]
34. Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.
Ariëns LFM; Gadkari A; van Os-Medendorp H; Ayyagari R; Terasawa E; Kuznik A; Chen Z; Bégo-Le Bagousse G; Lu Y; Rizova E; Graham NMH; Pirozzi G; De Bruin-Weller M; Eckert L
Acta Derm Venereol; 2019 Sep; 99(10):851-857. PubMed ID: 31099402
[TBL] [Abstract][Full Text] [Related]
35. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD).
Simpson EL; Gadkari A; Worm M; Soong W; Blauvelt A; Eckert L; Wu R; Ardeleanu M; Graham NMH; Pirozzi G; Sutherland ER; Mastey V
J Am Acad Dermatol; 2016 Sep; 75(3):506-515. PubMed ID: 27268421
[TBL] [Abstract][Full Text] [Related]
36. Severe eczema in Wiskott-Aldrich syndrome-related disorder successfully treated with dupilumab.
Alzahrani F; Miller HK; Sacco K; Dupuy E
Pediatr Dermatol; 2024; 41(1):143-144. PubMed ID: 37469225
[TBL] [Abstract][Full Text] [Related]
37. Superimposed linear atopic dermatitis treated with dupilumab.
Leszczynska MA; Trainor MA; Henkel E; Keeling BH; Diaz LZ
Pediatr Dermatol; 2021 Sep; 38(5):1377-1378. PubMed ID: 34272754
[TBL] [Abstract][Full Text] [Related]
38. Success of dupilumab as a monotherapy in an adult patient affected by severe uncontrolled asthma and atopic dermatitis.
Tolino E; Proietti I; Sarni A; Bernardini N; Mambrin A; Balduzzi V; Maddalena P; Marchesiello A; Michelini S; Volpe S; Skroza N; Potenza C
Dermatol Ther; 2021 Jan; 34(1):e14596. PubMed ID: 33244860
[No Abstract] [Full Text] [Related]
39. Monoclonal antibodies against interleukin 13 and interleukin 31RA in development for atopic dermatitis.
Hamann CR; Thyssen JP
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S37-S42. PubMed ID: 29248521
[TBL] [Abstract][Full Text] [Related]
40. A critical appraisal and implications of the new National Institute for Health and Care Excellence guideline on dupilumab for treating moderate-to-severe atopic eczema.
Weidinger S; Apfelbacher C
Br J Dermatol; 2019 Mar; 180(3):435-437. PubMed ID: 30821391
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
